Subsequent chemotherapy regimes are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma - Ansell, SM; Ristow, KM; Habermann, TM (J Clin Oncol, 2002)